GlassScriptPhysician profile
Udaya G Joseph
NPI 1578535720
$7,952.25
in general payments reported to CMS, 2019-2025
72 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $103 · 2021: $457 · 2022: $950 · 2023: $1,838 · 2024: $2,255 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,487 · Travel and Lodging: $269 · Education: $49.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.98 |
| Travel and Lodging | $269.06 |
| Education | $49.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $661.23 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $573.62 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $558.48 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $442.73 | 2022-2025 | |
| Gilead Sciences, INC. | $352.35 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $264.93 | 2019-2025 | Phesgo, Tecentriq, Venclexta |
| Celgene Corporation | $261.85 | 2019-2025 | Reblozyl, Abecma, Pomalyst |
| Pfizer INC. | $255.94 | 2019-2025 | |
| Janssen Biotech, INC. | $208.52 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Beigene USA, INC. | $201.05 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $199.56 | 2022-2025 | Opdualag, Opdivo, Breyanzi |
| Genmab U.S., INC. | $180.20 | 2021-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $166.85 | 2019-2024 | |
| Adaptive Biotechnologies Corporation | $161.50 | 2022-2025 | Clonoseq |
| Atricure, INC. | $156.25 | 2022 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gen-Probe, INC. | $149.66 | 2023 | Btx |
| Abiomed | $145.77 | 2025 | |
| Genentech, INC. | $144.87 | 2024 | Itovebi |
| Sirtex Medical INC | $140.36 | 2025 | Sir-Spheres Microspheres |
| Abbvie INC. | $135.17 | 2023-2025 | |
| Stemline Therapeutics INC. | $131.60 | 2020-2025 | Orserdu, Elzonris |
| Esperion Therapeutics, INC. | $122.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $112.58 | 2020-2025 | Enhertu, Tagrisso |
| Shire North American Group INC | $112.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $108.84 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $107.00 | 2021-2024 | |
| Amgen INC. | $105.43 | 2019-2023 | Kyprolis, Blincyto |
| Silk Road Medical, INC. | $104.63 | 2021 | |
| G1 Therapeutics, INC. | $99.99 | 2021 | |
| Array Biopharma INC | $94.09 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Kyowa Kirin, INC. | $92.31 | 2021-2025 | Poteligeo |
| Eisai INC. | $89.22 | 2019-2025 | |
| Tempus Ai, INC | $86.99 | 2024 | |
| Medtronic, INC. | $82.19 | 2024 | Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.42 | 2022-2025 | |
| Incyte Corporation | $71.03 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $51.99 | 2019-2025 | Onivyde |
| Adc Therapeutics America, INC. | $51.71 | 2023-2025 | |
| Puma Biotechnology, INC. | $51.26 | 2022-2024 | |
| Springworks Therapeutics, INC. | $50.80 | 2024-2025 | Ogsiveo, Gomekli |
| Sumitomo Pharma America, INC. | $47.51 | 2024-2025 | Orgovyx |
| Novo Nordisk INC | $45.48 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $42.35 | 2022-2024 | Givlaari |
| Sobi, INC | $42.18 | 2024 | |
| Lilly USA, LLC | $37.81 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Kite Pharma, INC. | $36.88 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $34.02 | 2021-2024 | Monoferric |
| Rigel Pharmaceuticals, INC. | $33.41 | 2022-2023 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $33.32 | 2023-2024 | Iclusig, Fruzaqla |
| Karyopharm Therapeutics INC. | $32.31 | 2023-2024 | Xpovio |
| Glaxosmithkline, LLC. | $31.62 | 2022-2023 | Ojjaara |
| Seagen INC. | $29.87 | 2021-2023 | Adcetris |
| Emd Serono, INC. | $27.54 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $26.60 | 2022-2023 | Epkinly, Imbruvica |
| Iovance Biotherapeutics, INC. | $23.43 | 2024 | Amtagvi |
| Astellas Pharma US INC | $20.60 | 2024 | Xospata |
| Coherus Oncology, INC. | $20.43 | 2023 | |
| Tersera Therapeutics LLC | $19.54 | 2023 | Zoladex |
| Dova Pharmaceuticals | $18.66 | 2021 | |
| Syndax Pharmaceuticals, INC. | $17.79 | 2025 | |
| Pharmaessentia USA Corporation | $17.65 | 2022 | |
| Acceleron Pharma, INC. | $17.47 | 2020 | |
| Immunocore Limited | $16.40 | 2025 | Kimmtrak |
| Cti Biopharma Corp. | $15.24 | 2023 | Vonjo |
| Taiho Oncology, INC. | $14.13 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.71 | 2024 | Empaveli |
| Grifols USA, LLC | $13.54 | 2020 | |
| Morphosys, US INC. | $13.40 | 2021 | |
| Blueprint Medicines Corporation | $13.13 | 2022 | |
| Fennec Pharmaceuticals, INC. | $13.12 | 2024 | Pedmark |
| Flowonix Medical Incorporated | $12.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udaya Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.